Free Trial

Biogen (BIIB) Stock Forecast & Price Target

Biogen logo
$153.14 -6.74 (-4.22%)
As of 01:47 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
1
Hold
20
Buy
11

Based on 32 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 32 analysts, 1 has given a sell rating, 20 have given a hold rating, and 11 have given a buy rating for BIIB.

Consensus Price Target

$180.04
17.57% Upside
According to the 32 analysts' twelve-month price targets for Biogen, the average price target is $180.04. The highest price target for BIIB is $275.00, while the lowest price target for BIIB is $118.00. The average price target represents a forecasted upside of 17.57% from the current price of $153.14.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
11 Buy rating(s)
12 Buy rating(s)
17 Buy rating(s)
Hold
20 Hold rating(s)
21 Hold rating(s)
20 Hold rating(s)
8 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$180.04$185.74$188.48$273.78
Forecasted Upside17.57% Upside32.04% Upside40.18% Upside47.45% Upside
Consensus RatingHoldHoldHoldModerate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biogen Stock vs. The Competition

TypeBiogenMedical CompaniesS&P 500
Consensus Rating Score
2.32
2.33
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside13.36% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Positive News

See Recent BIIB News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/6/2025Rothschild & Co Redburn
0 of 5 stars
 Boost TargetNeutral$149.00 ➝ $150.00-6.18%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (D+)
9/25/2025Jefferies Financial Group
2 of 5 stars
Andrew Tsai
Andrew Tsai
Not Rated
Initiated CoverageHoldBuy$190.00+38.01%
9/24/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/24/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform
9/24/2025Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold
9/12/2025Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$115.00 ➝ $118.00-17.89%
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$208.00 ➝ $219.00+73.42%
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$146.00 ➝ $144.00+15.25%
8/1/2025HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$187.00 ➝ $194.00+51.56%
7/21/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageHold$142.00+14.61%
6/12/2025Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$121.00-8.77%
5/7/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$207.00 ➝ $169.00+44.55%
5/5/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$185.00 ➝ $175.00+42.11%
5/2/2025Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Target$205.00+68.31%
5/2/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$265.00 ➝ $220.00+78.51%
5/2/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetOutperform$300.00 ➝ $255.00+110.87%
4/28/2025HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$118.00-0.71%
4/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-BuyHold
4/23/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetBuy$219.00 ➝ $197.00+63.72%
4/4/2025Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold
2/13/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetSector Outperform$244.00 ➝ $224.00+61.69%
2/13/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetMarket Perform$156.00 ➝ $139.00+1.30%
2/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetEqual Weight$165.00 ➝ $140.00+4.40%
2/11/2025Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetNeutral$178.00 ➝ $163.00+16.94%
2/11/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$160.00+12.25%
12/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold$175.00+16.64%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingNeutral$178.00+13.77%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoveragePeer Perform
10/31/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetEqual Weight$190.00 ➝ $180.00+2.18%
10/31/2024TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetBuy$300.00 ➝ $275.00+56.24%
10/10/2024Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Perform
10/3/2024UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$234.00 ➝ $202.00+9.42%
9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight$292.00 ➝ $292.00+46.34%
1/7/2024BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 01:33 PM ET.


Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 4, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • Biogen Inc. has received an "outperform" rating from several analysts, indicating strong potential for growth and positive performance in the market.
  • The stock has a consensus target price of approximately $181.65, suggesting that analysts expect significant upside from the current levels.
  • Recent institutional investments, including a 6.0% increase in holdings by IFM Investors Pty Ltd, reflect growing confidence in Biogen Inc.'s future prospects.
  • The current stock price is around $140.66, which may present a buying opportunity for investors looking for value in the biotechnology sector.
  • Biogen Inc. has a solid financial foundation, with a current ratio of 2.50, indicating good short-term financial health and the ability to cover its liabilities.

Biogen
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Despite positive ratings, the stock has experienced volatility, with recent trading down about 1.8%, which may concern risk-averse investors.
  • Biogen Inc. has a relatively high number of analysts rating the stock as a "hold," indicating uncertainty about its short-term performance.
  • The company has a debt-to-equity ratio of 0.36, which, while manageable, suggests that it is not entirely free from debt obligations that could impact future growth.
  • Recent price target adjustments by analysts, including a reduction from $146.00 to $144.00, may signal caution regarding the stock's near-term outlook.
  • With a P/E ratio of 13.09, the stock may not be considered undervalued compared to its peers, which could limit its appeal to value investors.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 32 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $180.04, with a high forecast of $275.00 and a low forecast of $118.00.

32 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There is currently 1 sell rating, 20 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.

According to analysts, Biogen's stock has a predicted upside of 17.57% based on their 12-month stock forecasts.

Analysts like Biogen less than other "medical" companies. The consensus rating score for Biogen is 2.31 while the average consensus rating score for "medical" companies is 2.33. Learn more on how BIIB compares to other companies.


This page (NASDAQ:BIIB) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners